IDS Form PTO/SB/08: Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of

Complete if Known

Application Number Not Yet Assigned
Filing Date May 16, 2005
First Named Inventor Arreas M. ZEHIER et al.
Art Unit Not Yet Assigned
Examiner Name Not Yet Assigned
Attorney Docket Number 05552.1459

١										
U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS										
	Examiner Initials	Cite No.1	Document Number Number-Kind Code ² (# known)	Issue or Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant				

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶				
/L.C./	T	WO 03/040691 A2	05-15-2003	SCHOENBECK et al.						
	7	WO 98/20155	05-14-1998	CROW et al.						
	┪	WO 02/056015 A1	07-18-2002	CONOVER et al.						
/L.C./		WO 01/56593 A2	08-09-2001	CARMELIET et al.		1				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials			Translation
/L.C./		SCHÖNBECK, U. et al., "Soluble CD40L and Cardiovascular Risk in Women," CIRCULATION, Vol. 1 No. 19, pp. 2266-2268, (November 6, 2001).	
		PENG, D. Q. et al., "Elevated Soluble CD40 Ligand is Related to the Endothelial Adhesion Molecules in Patients with Acute Coronary Syndrome," Clinica Chimica Acta, Vol. 319, No. 1, pp. 19-26, (May 7, 2002).	\ /
		YAN, J. et al., "Clinical Implications of Increased Expression of CD40L in Patients with Acute Coronary Syndromes," Chinese Medical Journal, Vol. 115, No. 4, pp. 491-493, (April 2002).	17
		AUKRUST, P. et al., "Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina: Possible Reflection of T Lymphocyte and Platelet Involvement in the Pathogenesis of Acute Coronary Syndromes," CIRCULATION, Vol. 100, No. 6, pp. 614-620, (August 10, 1999).	\square
		HEESCHEN, C. et al., "CD40 Ligand Serum Levels Independently Predicts Outcome and Effect of Anti- Platelet Therapy in Patients with Unstable Angina," CIRCULATION, Vol. 106, No. 19 Supplement, p. II.402, XP008028499, (November 5, 2002).	Y
		GARLICHS, C. D. et al., "Patients with Acute Coronary Syndrome Express Enhanced CD40 Ligand/CD154 on Platelets," HEART, Vol. 86, No. 6, pp. 649-655, (December 2001).	Λ
		BAYES-GENIS, A. et al., "Identification of Pregnancy-Associated Plasma Protein A (PAPP-A) as New Marker of Acute Coronary Syndromes," Journal of The American College of Cardiology, Vol. 37, No. 2 Supplement A. p. 301A, XP008028486, (February 2001).	71
		VARO, N. et al., "Soluble CD40L: Risk Prediction After Acute Coronary Syndromes," CIRCULATION, Vol. 108, No. 9, pp. 1049-1052, (September 2, 2003).	//
	Т	BAYES-GENIS, A. et al., "Pregnancy-Associated Plasma Protein A As a Marker of Acute Coronary Syndromes," New England Journal of Medicine, Vol. 345, No. 14, pp. 1022-1029, (October 4, 2001).	
/L.C./		KHOSRAVI, J. et al., "Pregnancy Associated Plasma Protein-A: Ultrasensitive Immunoassay and Determination in Coronary Heart Disease," Clinical Biochemistry, Vol. 35, No. 7, pp. 531-538, (2002).	1

Examiner Signature	/Lisa Cook/	Date Considered	12/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					10534985 - GAU:		
IDS Form PTO/S	B/08: Substitute for fo	m 1449A/PTO		Complete if Known			
				Application Number	Not Yet Assigned		
INF	ORMATION I	DISCLOSI	IRF	Filing Date	May 16, 2005	٠	
	TEMENT BY			First Named Inventor	Anreas M. ZEIHER et al.	•	
317	VIEWENI D	APPLICA	-CIV I	Art Unit	Not Yet Assigned	•	
	(Use as many sheet	s as necessary)		Examiner Name	Not Yet Assigned	٠	
Sheet	2	of	2	Attomey Docket Number	05552.1459	٠	
		•				٠	

Examiner	Cite			Name of Patentee or	Pages, Columns, Lines, Where
Initials		Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
_	-				
		No. of Concession, Name of			
$\overline{}$		- Control of the Cont			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ⁹ Number ¹⁰ Kind Code ¹¹ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ¹²			
ALC: UNIVERSAL PROPERTY.	***************************************					or description of the second			
			-						

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	clude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazlne, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/L.C./		DENKTAS, A. E. et al., "Pregnancy Associated Plasma Protein-A Levels Are Elevated in Patients With Unstable Angina," European Heart Journal, The European Society of Cardiology, XX, Vo. 23, No. ABSTR SUPPL. p. 466, XP008028493, (August 31, 2002).			/	
		HAJEK, P. et al., "Pregnancy-Associated Plasma Protein a (PAPP-a) in Determination of Unstable Coronary Plaque," European Heart Journal, Vol. 23, No. Abstract Supplement, p. 293, XP008028492, (2002).	1		_	
		FUTTERMAN, L. G. et al., "Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A," American Journal of Critical Care, Vol. 11, No. 2, pp. 168-172, (March 2002).		Λ		
		MAGLIONE, D. et al., "Recombinant Production of PIGF-1 and Its Activity in Animal Models," IL FARMACO, Vol. 55, pp. 165-167, (2000).				
/L.C./		LUTTUN, A. et al., "Revascularization of Ischemic Tissues by PfiGF Treatment, and Inhibition of Tumor angiogenesis, Arthritis and Atherosclerosis by Anti-Fit1," Nature Medicine, Vol. 8, No. 8, pp. 831-840, (August 2002).	7		1	
-	***************************************		-	opposite the same	-	
					_	

Examiner- Signature	/Lisa Cook/	Date Considered	12/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.